Interleukin-12 serum level has prognostic value in patients with ST-segment elevation myocardial infarction

Heart Lung. 2016 Jul-Aug;45(4):336-40. doi: 10.1016/j.hrtlng.2016.03.007. Epub 2016 Apr 16.

Abstract

Objectives: The study aimed to evaluate whether serum inflammatory markers have prognostic value in patients with ST-segment elevation myocardial infarction (STEMI).

Background: The role of cytokine-driven inflammation in the development of postdischarge complications after STEMI is obscured.

Methods: We recruited 214 patients who were admitted within 24 h of STEMI onset to our Institute. IL-1α, -6, -8, -10, -12, TNF-α, and CRP serum levels were measured on the 10-14th day after STEMI onset.

Results: Serum levels of IL-12, TNF-α, and CRP were significantly higher in patients with 3 affected coronary arteries compared to those with 1 affected coronary artery. However, only Killip class II-IV at admission and IL-12 serum level ≥90.0 pg/mL were defined as statistically significant predictors of adverse outcome after 1 year of follow-up.

Conclusion: IL-12 serum level may be suggested as a candidate prognostic marker if measured 10-14 days after STEMI onset.

Keywords: Atherosclerosis; Inflammation; Interleukin-12; Prognosis; ST-segment elevation myocardial infarction.

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin-12 / blood*
  • Male
  • Middle Aged
  • Prognosis
  • ST Elevation Myocardial Infarction / blood*
  • Time Factors

Substances

  • Biomarkers
  • Interleukin-12